Evaluation of QT Liability for PF‐05251749 in the Presence of Potential Circadian Rhythm Modification

• Autors principals: Yeamin Huh (Autor), Danny Chen (Autor), Steve Riley (Autor), Cheng Chang (Autor), Timothy Nicholas (Autor)
• Format: Llibre
• Publicat: Wiley, 2020-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

PF‐05251749 is a dual inhibitor of casein kinase 1 δ/ε, key regulators of circadian rhythm. As a result of its mechanism of action, PF‐05251749 may also change the heart rate corrected QT (QTc) circadian rhythm, which may confound detection of drug‐induced QTc prolongation. In this analysis, a nonli...